MetaCap

Tenax Therapeutics Inc. (TENX)

NASDAQ: TENXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.25-0.14 (-10.07%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TENX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$56.92M
EPS (TTM)
-$1.39
52-week range
1.24 – 19.40
Day range
1.24 – 1.35
Volume / Avg
2.28M / 3.15M
Beta
—

52-week range

$1.24$19.40

TENX stock today

Tenax Therapeutics (TENX) closed at $1.25 on Nov 20, down 10.07% (-$0.14), versus the S&P 500's 3.70% decline. Shares are 93.6% below their 52-week high of $19.40, set on Jul 9, 2026 and 0.8% above the 52-week low of $1.24, near the bottom of the past year's range. TENX is down 89.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 84.7%.

Tenax Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tenax Therapeutics

Company profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Christopher T. Giordano
Headquarters
Chapel Hill, NC
Employees
14

Financial highlights

Full financials

In fiscal 2025, Tenax Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Tenax Therapeutics reported a net loss of $52.6 million, compared with a loss of $17.6 million a year earlier. Diluted earnings per share came in at -$1.34.

Tenax Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0———
Growth—————
Net income$-52.60M$-17.60M$-7.71M$11.05M$-32.47M
EPS (diluted)$-1.34$-1.15$-31.04—$-1.58

Analyst forecast

Forecast

Consensus (10 analysts)

none

Avg. price target

$12.56+904.80%

  • Strong buy 1
  • Buy 5
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $36.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.31 vs $-0.35
Surprise
+11.43%

TENX news

All TENX news

Tenax Therapeutics peers

Health Care sector
TENX peer companies
CompanyPrice% ChgMarket capCompare
IBIOiBio Inc.0.8001-0.11%$56.37Mvs TENX
KZIAKazia Therapeutics Limited ADR4.92-8.38%$56.22Mvs TENX
AZRAzora Therapeutics Inc.3.85-0.52%$55.00Mvs TENX
RANIRani Therapeutics Holdings Inc. Class A0.5111-11.97%$59.03Mvs TENX
BOLDBoundless Bio Inc.2.32-2.52%$54.78Mvs TENX
XLOXilio Therapeutics Inc.7.56-1.11%$53.40Mvs TENX
CTORCitius Oncology Inc.0.5035-10.95%$53.25Mvs TENX
XBITXBiotech Inc.1.73+2.98%$52.74Mvs TENX

Indexes, lists and sector

Tenax Therapeutics stock FAQ

What is Tenax Therapeutics's stock price today?

TENX last traded at $1.25 as of Nov 20, 4:00 PM EST, down 10.07% on the day. Prices are delayed at least 15 minutes.

Does Tenax Therapeutics pay a dividend?

No. Tenax Therapeutics does not currently pay a regular cash dividend.

Who is Tenax Therapeutics's CEO?

Mr. Christopher T. Giordano is the chief executive officer of Tenax Therapeutics Inc., which has about 14 employees.

Has TENX ever split its stock?

Yes. The most recent TENX stock split was a 1-for-80 split on Jan 3, 2024, one of 5 splits on record.

What is the TENX 52-week high?

The 52-week high for TENX is $19.40 and the 52-week low is $1.24. The stock is currently 93.6% below its high.

Compare TENX